Inovio Pharmaceuticals held its fourth-quarter 2024 earnings call on March 18, 2025, at 4:30 p.m. ET, discussing the financial results for the period ending December 31, 2024. The meeting, which was webcast live, included prepared remarks, a question-and-answer segment, and involved key executives such as Dr. Jackie Shea, Dr. Mike Sumner, Peter Kies, and Steve Egge.
During the call, Jennie Wilson from Investor Relations introduced the management team and outlined the company’s focus and future plans. Dr. Jackie Shea highlighted the significant progress made in 2024 and INOVIO’s commitment to transitioning into a commercial-stage company with a focus on DNA medicines. She emphasized the company’s main strategic priorities, including the Biologics License Application (BLA) submission for INO-3107, a lead candidate for treating recurrent respiratory papillomatosis (RRP), and further advancements in their commercial strategy and platform.
Dr. Mike Sumner detailed specific achievements with the INO-3107, reporting the resolution of manufacturing issues involving their CELLECTRA device. He announced plans for FDA-required device verification and discussed the projected timeline for BLA completion. Sumner also provided updates on clinical findings, indicating that patients treated with INO-3107 demonstrated significant, sustained reductions in surgeries needed over a three-year period, which strengthens its potential as a preferred non-surgical treatment for RRP.
Steve Egge discussed the commercial landscape for INO-3107, emphasizing the importance of a non-surgical option for RRP patients. He reassured that the market research favored INO-3107, and the company was making significant progress in commercial preparations, foreseeing a small, efficient field force footprint due to the concentration of RRP cases.
In addition to INO-3107, Dr. Shea touched upon the company’s efforts in developing next-generation DNA medicines, highlighting the DNA-encoded monoclonal antibodies (DMAbs) technology. This proof-of-concept trial for COVID-19 showed promising results in durable antibody production without anti-drug antibody rejection, indicating potential long-term applications.
Financial officer Peter Kies presented the financial overview, signifying a reduction in operational expenses and noting the raised capital through equity offerings. He assured that the current cash reserves could support operations into the first quarter of 2026, not accounting for potential further funding activities.
Throughout the Q&A session, various analysts queried the timeline for BLA submissions, the resolution of device issues, potential production antibody halting, commercial strategy, and expectations for INO-3107’s market impact. The management team affirmatively addressed these inquiries, expressing confidence in their strategies and the anticipated market reception for INO-3107 and other pipeline projects.
In closing, Dr. Shea reiterated INOVIO’s commitment to advancing DNA medicines and improving patient outcomes, particularly emphasizing the importance of minimizing surgeries for RRP patients.
